Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 NKG2D Lymphocytes in Alopecia Areata Patients
TLDR EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.
The study demonstrated that Epigallocatechin-3 Gallate (EGCG) inhibited the STAT-1/JAK2/IRF-1/HLA-DR/HLA-B signaling pathway and reduced the number of CD8 MKG2D lymphocytes in patients with alopecia areata (AA). Conducted on 30 AA patients and 30 healthy controls, the research showed that EGCG at concentrations of 20-40 µM significantly reduced phosphorylated STAT1 and downstream gene expression, decreased inflammatory T cell subsets, and modulated cytokine levels. These findings suggested that EGCG could help maintain immune privilege in hair follicles and offer a safer, cost-effective therapeutic alternative to JAK inhibitors for AA treatment.
